Brand Name
Vimizim
Generic Name
Elosulfase
View Brand Information FDA approval date: February 14, 2014
Classification: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Form: Injection
What is Vimizim (Elosulfase)?
Vimizim is indicated for patients with Mucopolysaccharidosis type IVA . Vimizim is a hydrolytic lysosomal glycosaminoglycan -specific enzyme indicated for patients with Mucopolysaccharidosis type IVA .
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment